Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

MRC Laboratory of Molecular Biology Alumni Awarded Nobel Prize for Chemistry

Published: Monday, October 14, 2013
Last Updated: Monday, October 14, 2013
Bookmark and Share
Professor Michael Levitt, Professor Arieh Warshel and Professor Martin Karplus awarded the 2013 Nobel Prize in Chemistry.

This latest accolade takes the total number of Nobel Prizes awarded for work undertaken at the much-lauded Laboratory of Molecular Biology to 10 and the total number of prizes awarded to MRC-funded scientists to 21 in its 100 year history.
A key part of the Nobel Prize-winning research was undertaken at the MRC Laboratory of Molecular Biology (LMB), in the Structural Studies Division, in the 1970s. Together the work of all three LMB alumni has been developed further and enables modern chemists to simulate complex chemical reactions on a computer. This ability has allowed for much deeper understanding of how chemical processes happen.
Michael Levitt came to LMB as a PhD student in 1968, having first met Arieh Warshel while working as a visitor at the Weizmann Institute, Israel. At the Weizmann, Michael had become interested in protein conformation analysis and had written a general computer programme for studying the conformations of small molecules. He realised that the same programme could form the basis of a system for studying larger molecules. It was this system that Michael developed at LMB during his PhD work.
Martin Karplus, who had a research group in Harvard, was a visitor to LMB from1969 to 1970. He and Arieh worked together at Harvard in the early 1970s; Arieh combined his work with Michael on the classical computer program with Martin’s work on quantum physics. In 1972 Martin and Arieh published a paper showing for the first time how to combine classical and quantum physics when modelling retinal, a molecule embedded in the retina of the eye.
After undertaking post-doctoral work at the Weizmann, Michael returned to the LMB in 1974 and was joined by Arieh. During this time the final obstacles were overcome and two important papers were published in 1975 and 1976. The 1976 paper was the first computerised model of an enzymatic reaction, and for the first time allowed any kind of chemical reaction to be simulated involving any kind of molecule, irrespective of size.
Michael recently reflected on lessons learned during his time at the LMB and working with director Professor Max Perutz in a chapter for the book Memories and Consequences: Visiting Scientists at the MRC Laboratory of Molecular Biology, Cambridge. He wrote:
“In compiling these lessons, it became clear that Max Perutz had influenced me more than anyone else. I have published papers with Max, Francis [Crick] and Aaron [Klug], worked most closely with Aaron Klug and spent two years as Francis Crick’s only postdoctoral fellow shortly after he moved to the Salk Institute in 1977. Max Perutz’s influence on me has been like a fine wine, a little strange at first but maturing over 50 years to be a guiding light to me and, I imagine, to countless others.”
Professor Richard Henderson, former Director at the MRC Laboratory of Molecular Biology and former head of the Structural Studies Division, commented:
“Their early work on energy minimisation and its evolution into molecular dynamics has developed into a world-wide industry. It has permeated into all aspects of structural biology, from protein folding to drug design, to supramolecular interactions. Hopefully, it will soon be possible to compute the structure of almost everything, even if not with perfect accuracy.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MRC Delivering on the Life Sciences Strategy, One Year On
The Medical Research Council has made significant progress in implementing the measures outlined in last year’s Strategy for UK Life Sciences, according to a progress update published by the Government.
Tuesday, December 11, 2012
MRC and AstraZeneca Scoop Prestigious SCRIP Award
The innovative collaboration between the Medical Research Council and AstraZeneca has won the ‘Best Partnership Alliance’ award at the annual SCRIP Awards.
Tuesday, December 04, 2012
Medical Research Council Technology and Pharmidex Announce Drug Discovery Collaboration
Pharmidex to provide all in vivo ADME/PK drug discovery support to the MRCT in 2010.
Thursday, April 15, 2010
Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos